Avelumab Doesn’t Improve Survival in Platinum-Refractory Ovarian Cancer
There was no improvement in progression-free or overall survival.
There was no improvement in progression-free or overall survival.
There was an improvement in second progression-free survival, but not overall survival, with niraparib.
Rucaparib prolonged progression-free survival.
There was no benefit with atezolizumab, regardless of PD-L1 status.
Researchers observed a “sharp” decline in public interest.
Efficacy differed by cancer type and KRAS status.
A minority of women met criteria to exit cervical cancer screening.
Data showed increases in endometrial cancer and obesity in women younger than 40.
This review discusses a consensus study on optimal management of tumor hypoxia in patients undergoing radiotherapy for cervical cancer.
The median progression-free survival was nearly 6 months longer in patients who underwent surgery.